PROQR THERAPEUTICS N.V. Unaudited Condensed Consolidated Statement of Financial Position

PROQR THERAPEUTICS N.V.

Consolidated Statement of Financial Position

	September 30, 2016		December 31, 2015
		1,000		1,000
Assets
Current assets
Cash and cash equivalents		64,921		94,865
Prepayments and other receivables		3,662		1,948
Social securities and other taxes		490		956
Total current assets		69,073		97,769
Property, plant and equipment		3,644		2,199
Intangible assets		103		141
Total assets		72,820		100,109
Liabilities and shareholders equity
Current liabilities
Borrowings		1,768
Finance lease liabilities				15
Trade payables		237		885
Social securities and other taxes		319		235
Pension premiums		22		16
Deferred income				144
Other current liabilities		5,415		4,191
Total current liabilities		7,761		5,486
Borrowings		3,625		4,824
Total liabilities		11,386		10,310
Shareholders equity
Shareholders equity		61,434		89,799
Total liabilities and shareholders equity		72,820		100,109

PROQR THERAPEUTICS N.V.

Unaudited Condensed Consolidated Statement of Profit or Loss and OCI

( in thousands, except share and per share data)

	Three month period ended September 30,			Nine month period ended September 30,
	2016			2015		2016	2015
		1,000			1,000		1,000		1,000
Other income		447			1,191		1,725		2,277
Research and development costs		(8,319	)		(6,000	)	(23,823	)	(16,907	)
General and administrative costs		(2,001	)		(1,458	)	(7,218	)	(4,838	)
Total operating costs		(10,320	)		(7,458	)	(31,041	)	(21,745	)
Operating result		(9,873	)		(6,267	)	(29,316	)	(19,468	)
Finance income and expense		(254	)		(50	)	(968	)	4,762
Result before corporate income taxes		(10,127	)		(6,317	)	(30,284	)	(14,706	)
Income taxes
Net loss attributable to equity holders of the Company		(10,127	)		(6,317	)	(30,284	)	(14,706	)
Other comprehensive income
Total comprehensive loss (attributable to equity holders of the Company)		(10,127	)		(6,317	)	(30,284	)	(14,706	)
Share information
Weighted average number of shares outstanding 1		23,346,856			23,345,170		23,346,390		23,342,386
Earnings per share attributable to the equity holders of the Company (expressed in Euro per share)
Basic loss per share 1		(0.43	)		(0.27	)	(1.30	)	(0.63	)
Diluted loss per share 1		(0.43	)		(0.27	)	(1.30	)	(0.63	)

PROQR THERAPEUTICS N.V.

Unaudited Condensed Consolidated Statement of Changes in Equity

	Number of shares		Total Share Capital		Share Premium	Equity Settled Employee Benefit Reserve	Translation Reserve		Accumulated Deficit		Total Equity
				1,000		1,000		1,000		1,000		1,000		1,000
Balance at January 1, 2015		23,338,154		934		123,581		687				(15,798	)	109,404
Net loss												(14,706	)	(14,706	)
Recognition of share-based payments								919						919
Share options exercised		7,684		0		14								14
Balance at September 30, 2015		23,345,838		934		123,595		1,606				(30,504	)	95,631
Balance at January 1, 2016		23,345,965		934		123,595		1,899		1		(36,630	)	89,799
Net loss												(30,284	)	(30,284	)
Other comprehensive income										0				0
Recognition of share-based payments								1,917						1,917
Share options exercised		891		0		2								2
Balance at September 30, 2016		23,346,856		934		123,597		3,816		1		(66,914	)	61,434

PROQR THERAPEUTICS N.V.

Unaudited Condensed Consolidated Statement of Cash Flows

	Three month period ended September 30,			Nine month period ended September 30,
	2016			2015		2016	2015
		1,000			1,000		1,000		1,000
Cash flows from operating activities
Net result		(10,127	)		(6,317	)	(30,284	)	(14,706	)
Adjustments for:
Depreciation		284			126		978		338
Share-based compensation		628			300		1,917		919
Financial income and expenses		254			50		968		(4,762	)
Changes in working capital		(1,843	)		(527	)	(551	)	472
Cash used in operations		(10,804	)		(6,368	)	(26,972	)	(17,739	)
Corporate income tax paid
Interest received/(paid)		11			104		77		281
Net cash used in operating activities		(10,793	)		(6,264	)	(26,895	)	(17,458	)
Cash flow from investing activities
Purchases of intangible assets									(28	)
Purchases of property, plant and equipment		(422	)		(56	)	(2,495	)	(1,093	)
Net cash used in investing activities		(422	)		(56	)	(2,495	)	(1,121	)
Cash flow from financing activities
Proceeds from exercise of share options					8		2		14
Proceeds from borrowings							193		1,254
Redemption of financial lease					(7	)	(15	)	(27	)
Net cash generated by financing activities					1		180		1,241
Net increase/(decrease) in cash and cash equivalents		(11,215	)		(6,319	)	(29,210	)	(17,338	)
Currency effect cash and cash equivalents		(175	)		(51	)	(734	)	4,614
Cash and cash equivalents, at beginning of the period		76,311			106,382		94,865		112,736
Cash and cash equivalents at the end of the period		64,921			100,012		64,921		100,012

Full Press Release Details